Immogen Halts Lung Cancer Drug Trial Following Patient Death
Immogen Inc. announced Wednesday that it is discontinuing a mid-stage clinical trial for its experimental drug IMGN901.
About the Halted Immogen Clinical Trials
According to Reuters, an independent monitoring panel recommended that treatment of patients with the experimental small-cell lung cancer drug be halted following data linking the drug to increased risk of infection and infection related death.
In the trial, IMGN901 was being tested in combination with two other chemotherapy drugs, carboplatin and etopeside.
Currently, one death has been reported among the 198 patients participating in the trial. Rates of infection have yet to be released.
Other IMGN901 Clinical Trials
Immogen’s IMGN901 has been tested as a treatment of various other cancers in three other trials according to ClinicalTrials.Gov:
- NCT00991562 – Multiple Meyloma
- NCT00346255 – Multiple Meyloma
- NCT00346385 – Ovarian Cancer/Merkel Cell Carcinoma
Contact an Experience Clinical Trial Attorney
Thomas J. Henry are leaders in the area clinical trial litigation. Our Defective Drug and Products Division have extensive knowledge and resources in order to represent our clients efficiently and aggressively. Our Defective Drug and Products Division represent a multitude of people who are battling against manufacturers of medical devices and/or defective pharmaceuticals.
If you or a loved one have been injured by or have developed serious side-effects while participating in a clinical trial, contact Thomas J. Henry immediately. We represent clients/victims all over the country. We are available 24/7, nights and weekends.